Ablexis
PrivateLast Round
M&A
Jun 21, 2018
Total Funding Raised
$12M
Company Overview
Ablexis operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A round in June 2010.
Ablexis is a biotechnology company that provides the AlivaMab Mouse, a transgenic mouse platform for the discovery of therapeutic antibodies.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ablexis Comparables
Compare Ablexis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbTherx, Inc. | 87% | |
| OmniAb Inc. | 85% | |
| Harbour BioMed | 82% |
For institutional investors. Book with your work email.
Ablexis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jun 21, 2018 | ||||
| Series A | Jun 2, 2010 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ablexis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | M&A |
| Pfizer Ventures | Series A |
| Third Rock Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Monthly visitors grew 95% MoM.
- Nov 10, 2025
Monthly visitors increased 43% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 14, 2026
Ablexis grants Novo Nordisk A/S a non-exclusive license to use AlivaMab Mouse platforms and strains to discover, develop, and commercialize biologics comprising AlivaMab antibodies in California on Oct 14th '26.
For institutional investors. Book with your work email.
Ablexis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ablexis's valuation, stock price, and market status.
Is Ablexis a public or private company?
Ablexis is a private company.
What is the current stock price of Ablexis?
Ablexis is a private company, so its shares have no public market price. Caplight tracks Ablexis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ablexis worth (valuation)?
Valuation information for Ablexis is not publicly available.
Can I buy Ablexis stock?
Ablexis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ablexis's last funding round?
Ablexis's most recent funding round was M&A on June 21, 2018.
Who are the main investors in Ablexis?
Key investors in Ablexis include Deerfield Management, Third Rock Ventures.
Will Ablexis IPO soon?
No public IPO plans have been announced for Ablexis.
How can I track Ablexis secondary market activity?
Caplight tracks bids, offers, and trades in Ablexis's shares on secondary markets.